- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- ATA188, Placebo
- Biological · Drug
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- EBV Viremia, CMV Viremia
- Interventions
- Valganciclovir, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Interventions
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Biological
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Interventions
- Tabelecleucel, Pembrolizumab
- Biological
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Duarte, California • Palo Alto, California • Boston, Massachusetts + 3 more
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Interventions
- EBV-specific T cells (EBV-CTLs)
- Biological
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York